Cargando…
Combination of denosumab and biologic DMARDs in inflammatory muscle-skeletal diseases and connective tissue diseases
OBJECTIVE: Osteoporosis (OP) can complicate the course of rheumatic musculoskeletal diseases (RMDs) and connective tissue diseases (CTDs). Denosumab, a monoclonal antibody against RANK-L, showed beneficial effect in rheumatoid arthritis in inhibiting radiographic progression and erosive burden. We t...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medical Research and Education Association
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10176229/ https://www.ncbi.nlm.nih.gov/pubmed/35110179 http://dx.doi.org/10.5152/eurjrheum.2020.21162 |
_version_ | 1785040387107192832 |
---|---|
author | Bruni, Cosimo Cigolini, Cosimo Tesei, Giulia Cometi, Laura Bartoli, Francesca Fiori, Ginevra Nacci, Francesca Bellando-Randone, Silvia Guiducci, Serena Matucci-Cerinic, Marco |
author_facet | Bruni, Cosimo Cigolini, Cosimo Tesei, Giulia Cometi, Laura Bartoli, Francesca Fiori, Ginevra Nacci, Francesca Bellando-Randone, Silvia Guiducci, Serena Matucci-Cerinic, Marco |
author_sort | Bruni, Cosimo |
collection | PubMed |
description | OBJECTIVE: Osteoporosis (OP) can complicate the course of rheumatic musculoskeletal diseases (RMDs) and connective tissue diseases (CTDs). Denosumab, a monoclonal antibody against RANK-L, showed beneficial effect in rheumatoid arthritis in inhibiting radiographic progression and erosive burden. We tested the efficacy, safety, and persistence on the treatment of the combination of biologic disease-modifying antirheumatic drugs (bDMARDs)/denosumab versus bDMARD in patients with RMD and CTD. METHODS: This is a retrospective evaluation of a single center, including patients with RMD/CTD (including rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, systemic sclerosis, and overlap syndromes) treatment with bDMARD/denosumab, compared to age, gender, disease, bDMARD, and conventional synthetic disease-modifying antirheumatic drugs-matched controls. RESULTS: Twenty-eight bDMARD/denosumab patients and 49 bDMARD patients were eligible. Despite a statistically significant difference during the first-year efficacy (due to the different baseline timepoint), there was no difference in the efficacy profile in the second year of treatment and in the safety profile (including local, systemic, and serious adverse events). Moreover, no statistically significant difference in the persistence of bDMARD treatment over 2 years of evaluation was found. The combination of bDMARD and denosumab was not an independent predictor of disease flare or bDMARD treatment withdrawal. CONCLUSION: The combination of bDMARD and denosumab does not alter the efficacy and the safety profile of the bDMARD in patients with RMD/CTD. Future studies verifying the radiological disease inhibition could support denosumab use in RMD/CTD other than rheumatoid arthritis, when complicated by OP. |
format | Online Article Text |
id | pubmed-10176229 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Medical Research and Education Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-101762292023-05-12 Combination of denosumab and biologic DMARDs in inflammatory muscle-skeletal diseases and connective tissue diseases Bruni, Cosimo Cigolini, Cosimo Tesei, Giulia Cometi, Laura Bartoli, Francesca Fiori, Ginevra Nacci, Francesca Bellando-Randone, Silvia Guiducci, Serena Matucci-Cerinic, Marco Eur J Rheumatol Original Articles OBJECTIVE: Osteoporosis (OP) can complicate the course of rheumatic musculoskeletal diseases (RMDs) and connective tissue diseases (CTDs). Denosumab, a monoclonal antibody against RANK-L, showed beneficial effect in rheumatoid arthritis in inhibiting radiographic progression and erosive burden. We tested the efficacy, safety, and persistence on the treatment of the combination of biologic disease-modifying antirheumatic drugs (bDMARDs)/denosumab versus bDMARD in patients with RMD and CTD. METHODS: This is a retrospective evaluation of a single center, including patients with RMD/CTD (including rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, systemic sclerosis, and overlap syndromes) treatment with bDMARD/denosumab, compared to age, gender, disease, bDMARD, and conventional synthetic disease-modifying antirheumatic drugs-matched controls. RESULTS: Twenty-eight bDMARD/denosumab patients and 49 bDMARD patients were eligible. Despite a statistically significant difference during the first-year efficacy (due to the different baseline timepoint), there was no difference in the efficacy profile in the second year of treatment and in the safety profile (including local, systemic, and serious adverse events). Moreover, no statistically significant difference in the persistence of bDMARD treatment over 2 years of evaluation was found. The combination of bDMARD and denosumab was not an independent predictor of disease flare or bDMARD treatment withdrawal. CONCLUSION: The combination of bDMARD and denosumab does not alter the efficacy and the safety profile of the bDMARD in patients with RMD/CTD. Future studies verifying the radiological disease inhibition could support denosumab use in RMD/CTD other than rheumatoid arthritis, when complicated by OP. Medical Research and Education Association 2022-01-21 /pmc/articles/PMC10176229/ /pubmed/35110179 http://dx.doi.org/10.5152/eurjrheum.2020.21162 Text en © Copyright 2021 by Medical Research and Education Association https://creativecommons.org/licenses/by-nc/4.0/ Content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. (https://creativecommons.org/licenses/by-nc/4.0/) |
spellingShingle | Original Articles Bruni, Cosimo Cigolini, Cosimo Tesei, Giulia Cometi, Laura Bartoli, Francesca Fiori, Ginevra Nacci, Francesca Bellando-Randone, Silvia Guiducci, Serena Matucci-Cerinic, Marco Combination of denosumab and biologic DMARDs in inflammatory muscle-skeletal diseases and connective tissue diseases |
title | Combination of denosumab and biologic DMARDs in inflammatory muscle-skeletal diseases and connective tissue diseases |
title_full | Combination of denosumab and biologic DMARDs in inflammatory muscle-skeletal diseases and connective tissue diseases |
title_fullStr | Combination of denosumab and biologic DMARDs in inflammatory muscle-skeletal diseases and connective tissue diseases |
title_full_unstemmed | Combination of denosumab and biologic DMARDs in inflammatory muscle-skeletal diseases and connective tissue diseases |
title_short | Combination of denosumab and biologic DMARDs in inflammatory muscle-skeletal diseases and connective tissue diseases |
title_sort | combination of denosumab and biologic dmards in inflammatory muscle-skeletal diseases and connective tissue diseases |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10176229/ https://www.ncbi.nlm.nih.gov/pubmed/35110179 http://dx.doi.org/10.5152/eurjrheum.2020.21162 |
work_keys_str_mv | AT brunicosimo combinationofdenosumabandbiologicdmardsininflammatorymuscleskeletaldiseasesandconnectivetissuediseases AT cigolinicosimo combinationofdenosumabandbiologicdmardsininflammatorymuscleskeletaldiseasesandconnectivetissuediseases AT teseigiulia combinationofdenosumabandbiologicdmardsininflammatorymuscleskeletaldiseasesandconnectivetissuediseases AT cometilaura combinationofdenosumabandbiologicdmardsininflammatorymuscleskeletaldiseasesandconnectivetissuediseases AT bartolifrancesca combinationofdenosumabandbiologicdmardsininflammatorymuscleskeletaldiseasesandconnectivetissuediseases AT fioriginevra combinationofdenosumabandbiologicdmardsininflammatorymuscleskeletaldiseasesandconnectivetissuediseases AT naccifrancesca combinationofdenosumabandbiologicdmardsininflammatorymuscleskeletaldiseasesandconnectivetissuediseases AT bellandorandonesilvia combinationofdenosumabandbiologicdmardsininflammatorymuscleskeletaldiseasesandconnectivetissuediseases AT guiducciserena combinationofdenosumabandbiologicdmardsininflammatorymuscleskeletaldiseasesandconnectivetissuediseases AT matuccicerinicmarco combinationofdenosumabandbiologicdmardsininflammatorymuscleskeletaldiseasesandconnectivetissuediseases |